Yew Bio Pharm Group (YEWB) 0.2500 $YEWB Yew Bio-Pharm

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Yew Bio Pharm Group (YEWB) 0.2500 $YEWB

Yew Bio-Pharm Group Reports 2015 First Quarter Financial Results
PR Newswire - Thu May 14, 3:00PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three months ended March 31, 2015.

Yew Bio-Pharm Group Signs the Tripartite Joint Planting Auricularia Auricula Contract and Acquires Financial Supporting from BOCOM
PR Newswire - Mon May 11, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (YEWB), a major grower and seller of yew trees and yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that Harbin Yew Science and Technology Development Co., Ltd., a wholly-owned subsidiary of the Company ("HDS" entered into the Tripartite Joint Planting Auricularia Auricula Contract (the "Agreement" with Harbin Wuchang Xinlin Forestry Co., Ltd. ("Wuchang" and 15 Farmer Households (the "Farmers" to joint develop a project involving the growing, harvesting, selling Auricularia Auricula products (Commonly known as the Wood Ear Mushroom). To ensure the successful execution of the project, Mr. Zhiguo Wang, the CEO and principal stockholder of the Company, collateralized his personal assets with Bank of Communications ("BOCOM" Harbin Rongtong Branch to secure a loan to fund the project. Upon extensive review on the Company and the project, BOCOM has approved a loan totaling RMB 10,000,000 (approx. $1,630,000) to HDS. The proceeds of the loan will be used by HDS to implement its obligations under the Agreement.

Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results
PR Newswire - Wed Apr 01, 5:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and twelve-months ended December 31, 2014.

Yew Bio-Pharm Group Signs Sales Agreement and Receives Subsidy Grant from the Finance Department of Heilongjiang Province, China
PR Newswire - Mon Mar 23, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (YEWB) a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that the Company signed a Sales Agreement with Harbin Qihuicheng Trading Co., Ltd. Under the agreement, Yew Bio will contract Qihuicheng to provide Yew Extract that will be then used by Yew Bio to develop and produce Yew capsule in the U.S. health supplement market.

Yew Bio-Pharm to Enter U.S. Health Supplement Market With Two New Agaric Polysaccharide Products Focused on Enhancing Immunity
PR Newswire - Tue Dec 16, 7:00AM CST
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), today announced that it is entering into the U.S. health supplement market, through a collaboration with an American health supplement company to research and develop agaric polysaccharide (black fungus extract) and its related health supplements, which will be produced in the U.S. and sold to both American and Chinese markets. The new products are expected to launch in the first half of 2015.

Yew Bio-Pharm Group Reports Improved Financial Results For 2014 Third Quarter
PR Newswire - Mon Nov 17, 8:30AM CST
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and nine-months ended September 30, 2014.

Yew Bio-Pharm Establishes New Subsidiary to Focus on Organic Foods and Functional Beverages
PR Newswire - Tue Nov 04, 8:30AM CST
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), today announced the creation of a new subsidiary, Harbin Yew Food Co. LTD., to develop and cultivate black fungus. The company plans to operate three production lines to include black fungus polysaccharide, powder, tea and other packaged black fungus products. The move marks the Company's entrance into the organic food and functional beverage market.

Yew Bio-Pharm Applauds China State Forestry Administration's Creation of Subsidies to Encourage Chinese Medicinal Herb Crops
PR Newswire - Thu Oct 30, 8:30AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber, today applauded the creation of a subsidy program by the State Forestry Administration of China to promote the development and growth of Chinese medicinal herb crops.

Yew Bio-Pharm Signs Exclusive Distribution Agreement with Carpal Aid to Market Carpal Tunnel Syndrome Product in China
PR Newswire - Mon Oct 13, 7:05AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China, today announced a multi-year exclusive distribution agreement with Carpal Aid to distribute its non-invasive medical device "Carpal Aid" for carpal tunnel syndrome throughout China.

Yew Bio-Pharm Group Reports 2014 Second Quarter Financial Results
PR Newswire - Thu Aug 14, 3:05PM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- and six-months ended June 30, 2014.

Yew Bio-Pharm Welcomes Two New Board Members
PR Newswire - Tue Jul 15, 7:00AM CDT
Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company" (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced the appointment of Tong Liu and Hengjiang (Henry) Pang to the Company's Board of Directors, effective August 1, 2014.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 144

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 263

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 159

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 242

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 327

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Honors Shaping Leadership Through Innovation

Updated Category News Views 52

Frost & Sullivan Institute: Leading By Example Alright, folks, we’re talking about the kind of business leadership that isn’t just about fattening the bottom line. The Frost & Sullivan Institute rolled out the carpet for companies that don’t just talk the talk—they walk the walk. This recognition isn't just another plaque for the wall; it's a pat on the back for...

Continue Reading
Boosting Franchise Performance Through Gamification with Batteries Plus

Updated Category News Views 204

Revolutionizing Franchise Excellence: The Plus Games Batteries Plus, a leader in the battery retail sector, has embarked on an exciting journey with its newly announced initiative called The Plus Games. This program is designed to transform franchisee training and sales strategies by gamifying the entire process. The objective? To cultivate exceptional performance and...

Continue Reading
Investigation into Eos Energy Enterprises' Potential Securities Fraud

Updated Category News Views 213

Investigation into Eos Energy Enterprises Pomerantz LLP is currently investigating claims concerning investors of Eos Energy Enterprises, Inc. (NASDAQ: EOSE). This inquiry raises questions about whether the company and some of its executives may have been involved in securities fraud or other fraudulent business practices. Recent Developments at Eos Energy Recently, Eos...

Continue Reading
Emerging Trends Transforming the Global Cold Brew Coffee Market

Updated Category News Views 184

Impact of Millennial Preferences on Cold Brew Coffee The cold brew coffee market is poised for significant growth, estimated to expand by USD 519.2 million within the forecast period. This growth is largely driven by changing consumer preferences, particularly among millennials who favor modern, convenient beverage choices. As more companies enter the market with...

Continue Reading
EMCOR Group, Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 74

EMCOR Group, Inc. Announces Quarterly Cash Dividend NORWALK, Conn. - EMCOR Group, Inc. (NYSE: EME) has proudly declared a regular quarterly cash dividend of $0.25 per common share. This announcement was made by the Board of Directors, showing their ongoing commitment to delivering value to shareholders. Dividend Payment Details The scheduled payment date for the upcoming...

Continue Reading